Pharmaceuticals
Ascletis Announces Positive Interim Data from the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Cure
HANGZHOU and SHAOXING, China, Sept. 29, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces positive interim data from the Phase IIb expansion cohort (the "Expansion Cohort") of subcutaneously administered PD-L1 antibody ASC22 (Envafolimab) for functional cure of ch...
2023-09-29 08:10
4204
Innovent and IASO Bio Present Updated Long-Term Follow-Up Data for BCMA CAR-T FUCASO® (Equecabtagene Autoleucel) at IMS 2023
82.4% of patients without prior CAR-T achieving Complete Response (CR) or better ROCKVILLE, Md. and SUZHOU, China, Sept. 29, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-qualit...
2023-09-29 08:00
4020
ALR Technologies Announces Patent Grant for Predictive A1C and Successful Results from Singapore General Hospital-led Study
SINGAPORE, Sept. 28, 2023 /PRNewswire/ -- ALR Technologies SG Ltd. ("ALRT" or the "Company") (OTCQB: ALRTF), a diabetes management company, announces the patent application titledMethod and System of Monitoring a Diabetes Treatment Plan("Predictive A1c") has been granted in Singapore and has rec...
2023-09-28 20:28
6724
Antengene To Present Results From Five Studies at 2023 SITC Annual Meeting
SHANGHAI and HONG KONG, Sept. 28, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for canc...
2023-09-28 08:30
2864
Everest Medicines Announces Approval of XERAVA® in Taiwan for the Treatment of Complicated Intra-Abdominal Infections in Adult Patients
SHANGHAI, Sept. 28, 2023 /PRNewswire/ -- Everest Medicines
2023-09-28 07:38
3807
Besins Healthcare Unveils State-of-the-Art Hormone Factory in Muel, Spain, Amplifying Global Production Capabilities by 30%
"A Milestone in European Pharmaceutical Manufacturing": Besins Healthcare Debuts Pioneering Plant to Address Soaring Global Demand for Hormones and to Fortify Europe's Medical Sovereignty MONACO, Sept. 27, 2023 /PRNewswire/ -- Besins Healthcare, a global lead in Women's and Men's Reproductive He...
2023-09-27 15:56
2415
HRH Princess Astrid of Belgium visits Telix's New European Manufacturing Facility in Brussels South
MELBOURNE, Australia and LIEGE, Belgium, Sept. 27, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) has welcomed Her Royal Highness,Princess Astrid, Princess of Belgium to Telix Manufacturing Solutions (TMS), the Company's recently inaugurated production facility,...
2023-09-27 12:00
3280
'Bayer For Her' Supporting 365 Days Conversations of Care to More Women in Asia
* Bridging the gap on lack of discussion amongst Asian women on their health concerns this World Contraception Day (WCD) SINGAPORE, Sept. 27, 2023 /PRNewswire/ -- Bayer Pharmaceuticals Division inAsia/Pacific announced today in conjunction with World Contraception Day, the inception of its 'Bay...
2023-09-27 10:00
3641
Latest Updates of Viva's Portfolio Companies
HONG KONG, Sept. 26, 2023 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies up to date and promotes the evolution of R&D and the su...
2023-09-26 21:06
3439
YS Biopharma Announces First Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine
GAITHERSBURG, Md., Sept. 26, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious dise...
2023-09-26 20:30
2526
Ascletis Announces Completion of Enrollment of 120 Patients in the Phase III Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma
--Based on prespecified interim analysis condition, 120 patients are likely to lead sufficient events for interim analysis of progression-free survival (PFS) HANGZHOU and SHAOXING, China, Sept. 26, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces the completion o...
2023-09-26 08:10
3475
"Kexing Biopharm 2023 Innovation Forum on Targeted Drug Delivery"
SHENZHEN, China, Sept. 25, 2023 /PRNewswire/ -- On September 15, "Kexing Biopharm 2023 Innovation Forum on Targeted Drug Delivery" successfully kicked off. This marks the first time in recent years that the Company has organized an event specifically focused on pharmaceutical R&D innovation. The...
2023-09-25 15:31
3186
Pierre Fabre Laboratories and Vernalis announce a drug discovery collaboration in oncology
CASTRES, France and CAMBRIDGE, England, Sept. 25, 2023 /PRNewswire/ -- Pierre Fabre Laboratories and Vernalis (R&D) Ltd ("Vernalis"), a fully owned subsidiary of HitGen Inc., are pleased to announce a long-term partnership to identify pre-clinical candidates against multiple oncology targets. ...
2023-09-25 15:00
2495
AffaMed Therapeutics Announces Clinical Trial Application Approval in Mainland China for Risuteganib (Luminate®) First-in-Class Candidate for the Treatment of Intermediate Dry AMD
SHANGHAI, Sept. 25, 2023 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global biotechnology company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products that address critical unmet medical needs in ophthalmological, neurological and psychi...
2023-09-25 09:00
4528
Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ESCC
SHANGHAI, Sept. 25, 2023 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696. HK) announced that the new drug application (NDA) for new indication of HANSIZHUANG (serplulimab injection), an innovative anti-PD-1 monoclonal antibody independently developed by the company, in combination with drugs...
2023-09-25 07:41
3483
Antengene Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031
- The Phase I "PERFORM" study will evaluate the safety and tolerability, pharmacology, immunogenicity, and preliminary efficacy of ATG-031 in patients with advanced solid tumors or B-cell non-Hodgkin's lymphoma (B-NHL). - ATG-031,discovered and developed in-house by Antengene,is the world's firs...
2023-09-21 18:05
3001
Yuyu Healthcare Conducts Global Promotion at Vitafoods Asia 2023
SEOUL, South Korea, Sept. 21, 2023 /PRNewswire/ -- Yuyu Healthcare will
participate in the Vitafoods Asia 2023 event inBangkok, Thailand with the goal
of entering the global market.
2023-09-21 14:06
6831
Lynk Pharmaceuticals Completes Series C2 Financing Round, with Total C Round Funding of 322 Million RMB
HANGZHOU, China, Sept. 21, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, today announced the successful completion of Series C2 financing. This round of financing was jointly participated by the Shaox...
2023-09-21 08:00
4812
Everest Medicines Enters into Collaboration and License Agreement with Kezar Life Sciences to Develop and Commercialize Zetomipzomib in Greater China and other Asian Markets
SHANGHAI, Sept. 21, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today it has entered into a collaboration and license...
2023-09-21 07:05
3837
European Commission Approves Menarini Group's ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation
* Each year in Europe more than 550,000 patients are diagnosed with breast cancer, of whom 70% have estrogen receptor (ER)-positive disease¹; more than 147,000 breast cancer patients inEurope die annually from the disease² * ORSERDU is the first treatment specifically for patients with ER+, HE...
2023-09-20 23:27
3436
Week's Top Stories
Most Reposted
Carro secures strategic investment from Orico
[Picked up by 294 media titles]
2026-09-18 16:29Agoda Begins Limited Public Beta of New AI Assistant That Turns Travel Ideas into Bookable Trips
[Picked up by 289 media titles]
2026-09-15 11:00
Avnet and The University of Hong Kong Open EMUS Lab to Accelerate AI Innovation and Commercialization in Hong Kong
[Picked up by 281 media titles]
2026-09-17 13:09
Tetra Pak and Soy Excellence Center Asia Host Regional Soy Food and Beverage Programme in Thailand
[Picked up by 268 media titles]
2026-09-18 11:51
Sovereign Investment Institutions Launch China-ASEAN Joint Investment Council
[Picked up by 267 media titles]
2026-09-16 09:09
Most Read
Agoda Begins Limited Public Beta of New AI Assistant That Turns Travel Ideas into Bookable Trips
2026-09-15 11:00
9761
Temporal Raises $550 Million in Series E Round: NYSE Content Update
2026-09-14 21:14
8135
Avnet and The University of Hong Kong Open EMUS Lab to Accelerate AI Innovation and Commercialization in Hong Kong
2026-09-17 13:09
7426
CLP Power Hosts AESIEAP CEO Conference 2026 in Hong Kong
2026-09-15 19:07
6644
